Features of 253 patients with de novo precursor B-cell ALL by CD20 status: pre-rituximab era
| Parameter/category . | No. (%) . | P (χ2) . | |
|---|---|---|---|
| CD20 negative (N = 133) . | CD20 positive (N = 120) . | ||
| Age, y | |||
| ≤ 30 | 52 (39) | 39 (33) | NS |
| 31-59 | 53 (40) | 60 (50) | NS |
| ≥ 60 | 27 (21) | 21 (17) | NS |
| Median (range) | 38 (15-80) | 39 (16-80) | NS |
| Performance status (Zubrod) | |||
| 0-1 | 109 (82) | 83 (69) | .02 |
| 2-3 | 24 (18) | 37 (31) | .02 |
| Sex | |||
| M | 83 (62) | 73 (61) | NS |
| F | 50 (38) | 47 (39) | NS |
| Leukocyte count (x109/L) | |||
| < 5 | 38 (28) | 46 (38) | NS |
| 5-29.9 | 52 (39) | 39 (33) | NS |
| ≥ 30 | 43 (32) | 35 (29) | NS |
| Hemoglobin (g/dL)/< 10 | 86 (65) | 86 (72) | NS |
| Platelet count (x109/L)/< 100 | 92 (69) | 98 (82) | .02 |
| Beta-2 microglobulin (mg/dL)/≥ 3 | 44 of 96 (45) | 35 of 80 (43) | NS |
| Peripheral blasts (%)/Yes | 119 (89) | 102 (85) | NS |
| Marrow blasts (%)/≥ 50 | 123 (93) | 111 (94) | NS |
| FAB | |||
| L1 (N = 119) | 38 (32) | 42 (38) | NS |
| L2 (N = 111) | 81 (70) | 69 (62) | NS |
| Karyotype | |||
| Diploid | 38 (29) | 32 (26) | NS |
| Philadelphia | 23 (17) | 29 (24) | NS |
| Hyperdiploid | 7 (5) | 12 (10) | NS |
| Hypodiploid | 2 (2) | 5 (4) | NS |
| Other | 29 (21) | 14 (12) | NS |
| Insufficient | 33 (25) | 25 (21) | NS |
| Marker expression higher than 20% | |||
| CD19 | 105 of 130 (81) | 105 of 118 (89) | .07 |
| CD13 or CD33 | 26 of 126 (21) | 11 of 109 (10) | .03 |
| Lactate dehydrogenase, LDH (U/L)/≥ 1400 | 66 (50) | 58 (48) | NS |
| Splenomegaly/Yes | 33 (25) | 39 (32) | NS |
| Hepatomegaly/Yes | 16 (12) | 18 (15) | NS |
| Lymphadenopathy/Yes | 49 (36) | 30 (25) | .04 |
| CNS leukemia/Yes | 3 (2) | 2 (2) | NS |
| CNS relapse risk | |||
| Low | 37 (28) | 46 (38) | NS |
| Indeterminate | 27 (20) | 12 (10) | NS |
| High | 69 (52) | 62 (51) | NS |
| Systemic risk classification | |||
| Low | 25 (19) | 30 (25) | NS |
| High | 106 (81) | 89 (74) | NS |
| Parameter/category . | No. (%) . | P (χ2) . | |
|---|---|---|---|
| CD20 negative (N = 133) . | CD20 positive (N = 120) . | ||
| Age, y | |||
| ≤ 30 | 52 (39) | 39 (33) | NS |
| 31-59 | 53 (40) | 60 (50) | NS |
| ≥ 60 | 27 (21) | 21 (17) | NS |
| Median (range) | 38 (15-80) | 39 (16-80) | NS |
| Performance status (Zubrod) | |||
| 0-1 | 109 (82) | 83 (69) | .02 |
| 2-3 | 24 (18) | 37 (31) | .02 |
| Sex | |||
| M | 83 (62) | 73 (61) | NS |
| F | 50 (38) | 47 (39) | NS |
| Leukocyte count (x109/L) | |||
| < 5 | 38 (28) | 46 (38) | NS |
| 5-29.9 | 52 (39) | 39 (33) | NS |
| ≥ 30 | 43 (32) | 35 (29) | NS |
| Hemoglobin (g/dL)/< 10 | 86 (65) | 86 (72) | NS |
| Platelet count (x109/L)/< 100 | 92 (69) | 98 (82) | .02 |
| Beta-2 microglobulin (mg/dL)/≥ 3 | 44 of 96 (45) | 35 of 80 (43) | NS |
| Peripheral blasts (%)/Yes | 119 (89) | 102 (85) | NS |
| Marrow blasts (%)/≥ 50 | 123 (93) | 111 (94) | NS |
| FAB | |||
| L1 (N = 119) | 38 (32) | 42 (38) | NS |
| L2 (N = 111) | 81 (70) | 69 (62) | NS |
| Karyotype | |||
| Diploid | 38 (29) | 32 (26) | NS |
| Philadelphia | 23 (17) | 29 (24) | NS |
| Hyperdiploid | 7 (5) | 12 (10) | NS |
| Hypodiploid | 2 (2) | 5 (4) | NS |
| Other | 29 (21) | 14 (12) | NS |
| Insufficient | 33 (25) | 25 (21) | NS |
| Marker expression higher than 20% | |||
| CD19 | 105 of 130 (81) | 105 of 118 (89) | .07 |
| CD13 or CD33 | 26 of 126 (21) | 11 of 109 (10) | .03 |
| Lactate dehydrogenase, LDH (U/L)/≥ 1400 | 66 (50) | 58 (48) | NS |
| Splenomegaly/Yes | 33 (25) | 39 (32) | NS |
| Hepatomegaly/Yes | 16 (12) | 18 (15) | NS |
| Lymphadenopathy/Yes | 49 (36) | 30 (25) | .04 |
| CNS leukemia/Yes | 3 (2) | 2 (2) | NS |
| CNS relapse risk | |||
| Low | 37 (28) | 46 (38) | NS |
| Indeterminate | 27 (20) | 12 (10) | NS |
| High | 69 (52) | 62 (51) | NS |
| Systemic risk classification | |||
| Low | 25 (19) | 30 (25) | NS |
| High | 106 (81) | 89 (74) | NS |
Positive, more than 20% CD20 expression; NS, not significant; FAB, French-American-British classification (L3 subtype excluded); CNS relapse risk: low, proliferative index (S+G2M) less than 14% and LDH less than 1400, high, proliferative index (S+G2M) 14% or more or LDH 1400 U/L or more, indeterminate, value unknown; systemic risk classification: high risk, WBC higher than 5 x 109/L, more than 1 course to CR; Philadelphia chromosome or CNS disease, low risk, none of these features.